Loading...

AKTX AKARI THERAPEUTICS PLC Management Changes 8-K Filing

KR T

KTX

AKARI THERAPEUTICS PLC

(AKTX)

2024 8-K

Ratio Change Announcement

Shareholder Meeting Outcomes

Equity Financing Completed

Shareholder Meeting Results

Investor Presentation

Delisting Notification

Management Change

Securities Offering

Funding Announcement

Notes Offering Closed

Financial Amendments

Share Purchase Agreement

Promissory Notes Issued

Investor Presentation Update

Equity Offerings

Financial Statements

Financial Results

CEO Appointment

Securities Offering

Corporate Update

Management Changes

Management Change

Management Changes

Merger Completion

Merger Approval

Delisting Notice

Merger Agreement

Financial Results

Annual General Meeting

Appointment of Interim Pres...

Private Placement

Financial Results Announcement

Restructuring and reorganis...

Management Changes

Financial Results Announcement

Private Placement Agreement

Merger Agreement

Private Placement

External Links:

Akari Therapeutics appointed Robert Bazemore as a new director and amended the compensation agreement for Interim CEO Samir Patel, while also providing updates on their merger with Peak Bio, which requires various approvals and conditions, including a minimum net cash of $13.5 million for Peak Bio and at least $10 million in net proceeds from a PIPE investment.

AI Assistant

AKARI THERAPEUTICS PLC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.